IFNG and colonic neoplasm: Stimulating ICs hold great therapeutic promise—urelumaband utomilumab (PF-05082566) are two anti-CD137 antibodies under development80 that appear promising in renal cell carcinomaand colon cancer among many others because they can stimulate cytotoxicT cells and enhance the production of interferon gamma (IFN-γ),which is crucial for anticancer effects.